SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Cadila receives tentative approval from USFDA for Doxepin HcI tablets

27 Feb 2013 Evaluate

Zydus Cadila has received tentative approval from USFDA for Doxepin Hcl tablets in the strengths of 3 mg and 6 mg. The estimated sales in 2012 as per IMS for Doxepin Hcl, which falls in the neuropsychiatry segment was $15.5 million. It is scheduled to be launched in June 2020 upon patent expiry.

The group now has 77 approvals and has so far filed 172 ANDAs since the commencement of the filing process in FY 2003-04.

The flagship company of Zydus Cadila Group, focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.

Zydus Lifesciences Share Price

942.55 3.35 (0.36%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×